Document is current
Any future updates will be listed below
-
Authors
Lombardo, Flavia L. http://orcid.org/0000-0001-6183-0735
Spila Alegiani, Stefania
Mayer, Flavia
Cipriani, Marta
Lo Giudice, Maria
Ludolph, Albert Christian
McDermott, Christopher J.
Corcia, Philippe
Van Damme, Philip
Van den Berg, Leonard H.
Hardiman, Orla
Nicolini, Gabriele
Vanacore, Nicola
Dickie, Brian
Albanese, Alberto
Puopolo, Maria
,
Tornese, Paolo
Cocco, Antoniangela
Matteoli, Michela
Lauranzano, Eliana
Malosio, Maria Luisa
Elia, Chiara Adriana
Chiò, Adriano
Manera, Umberto
Moglia, Cristina
Calvo, Andrea
Salamone, Paolina
Fuda, Giuseppe
Colosimo, Carlo
Spera, Cristina
Ranchicchio, Prabha Cristina
Stipa, Giuseppe
Frondizi, Domenico
Lunetta, Christian
Sansone, Valeria
Tarlarini, Claudia
Gerardi, Francesca
Silani, Vincenzo
Doretti, Alberto
Colombo, Eleonora
Demirtzidis, Gianluca
Tedeschi, Gioacchino
Trojsi, Francesca
Passaniti, Carla
Ballestrero, Stefania
Dorst, Johannes
Weiland, Ulrike
Fromm, Andrea
Wiesenfarth, Maximilian
Kandler, Katharina
Witzel, Simon
Otto, Markus
Schuster, Joachim
Meyer, Thomas
Maier, André
Kettemann, Dagmar
Petri, Susanne
Müschen, Lars
Wohnrade, Camilla
Sarikidi, Anastasia
Osmanovic, Alma
Grosskreutz, Julian
Rödiger, Annekathrin
Steinbach, Robert
Ilse, Benjamin
Smesny, Uta
Untucht, Robert
Günther, René
Vidovic, Maximilian
Shaw, Pamela
Collins, Alexis
Wollff, Helen
Walsh, Theresa
Tuddenham, Lee
Kazoka, Mbombe
White, David
Young, Stacy
Thompson, Benjamin
Madarshahian, Daniel
Chhetri, Suresh K.
Chaouch, Amina
Young, Carolyn A.
Arndt, Heike
Hanemann, Coliver
Lambert, Thomas
Beltran, Stephane
Couratier, Philippe
Esselin, Florence
Camu, William
De La Cruz, Elisa
Lemasson, Gwendal
Masrori, Pegah
Maguire, Sinead
Fogarty, Liz
Atoyebi, Toyosi
Obáin, Niamh Ní
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (755094)
- License Information
-
More Information
Article History
Received: 23 July 2023
Accepted: 22 August 2023
First Online: 5 December 2023
Declarations
:
: The TUDCA-ALS trial has been approved by all the involved national and local Ethical Committees (the full list is available in the published protocol). Informed consent was obtained from all study participants.
: Not applicable.
: Author AL declares participation in Advisory Boards of Roche Pharma AG, Biogen, Alector, and Amylyx. Author CJM reports consultancy with Biogen, Amylyx, and Cytokinetics. Author PV declares participation in Advisory Board meetings for Biogen, UCB, argenx, Cytokinetics, Ferrer, Muna Therapeutics, Augustine Therapeutics, Alector, Alexion, QurAlis, VectorY, and Amylyx (paid to institution) and grant from CSL Behring (E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders; paid to institution). Author OH declares participation in Advisory Boards for Accelsiors, Biogen Idec, Cytokinetics, NeuroSense Therapeutics, Neuropath Therapeutics, Novartis, Orion, Denali, and Wave Pharmaceuticals; role as principal investigator on the PRECISION ALS Project; Academic/Industry Collaboration funded by Science Foundation Ireland; Research collaboration with Biogen, Cytokinetics, and Ionis in delivering the IMPACT ALS survey and with Cytokinetics in delivering the REVEALS study of respiratory decline in ALS; editor-in-chief of ALS and the Frontotemporal Degeneration; editorial board member of the Journal of Neurology, Neurosurgery, and Psychiatry. Author GN declares that Bruschettini S.R.L is the pharmaceutical company providing the investigational medicinal product and industrial partner of the project, in which he is an employee as medical director. The remaining authors declare no competing interests.
